Announcement Samsung Biologics, a popular contract development and manufacturing organisation (CDMO), has declared that Samsung Biologics America, a fully owned U.S subsidiary, has signed a definitive deal to procure full Human Genome Sciences (HGS) from GSK. This smart strategy will protect Samsun...
Announcement Ipsen, a French-based biopharmaceutical company concentrating on marketing and drug development in neuroscience, rare disease and oncology spaces, has proudly revealed its exclusive licensing agreement for its SIM0613, an antibody-drug conjugate (ADC), to gain universal rights in Great...
Announcement Alvotech, a leading and promising biotechnology company excelling in the manufacture and establishment of biosimilar drugs for patients globally, showed excitement about its new launches. The launches are yet to land in the first-in-market biosimilar for Gobivaz® (golimumab) in Eur...
Announcement Cytokinetics received a green signal from the FDA for its cardiac myosin inhibitor, which has reserved the biotech to compete with Bristol Myers Squibb in the heart disease sector. This approval cased adult group of aficamten with symptomatic obstructive hypertrophic cardiomyopathy (oH...
Announcement Trump has been in the limelight since its tariffs storm that shook the trading, healthcare and other sectors as well. Recently, Trump has come up with some favourable and convincing deals with nine drugmakers. This purpose-built deal is to reduce the prices on the drugs for cash payers...
FDA’s Policy Initiatives The FDA’s guidance and various policies were at a pace this year. Neverthless the guidance on vaccines and rare disease have attracted most of the deals, with policy shifts focused on enhancing the FDA's efficiency. Alongside the inshoring of the U.S. manufactur...
Announcement Tolmar, Inc. has proudly declared that its extended indication for Rubraca® has finally received the U.S. Food and Drug Administration (FDA) stamp. The extended indication allows its use before chemotherapy for the qualified patients suffering from metastatic castration-resistant p...
Announcement Faron Pharmaceuticals Ltd., a leading clinical-level biopharmaceutical company, has entered a partnership deal to begin with the new investigator-initiated trial (IIT), BLAZE trial in the UK. The trial is organised through the smart partnership with The Institute of Cancer Research, Lo...
Announcement Novo Nordisk has now registered a new drug application to receive the FDA’s approval stamp. This decision by Novo stems from its competition with Lilly in the weight loss market so far. In a way, this move is an answer to Lilly and the company’s ongoing efforts to regain do...
Announcement The failure of Moderna faced on its deal cancellation by the Department of Health and Human Services, worth $760 million, which was in support of developing the vaccine named mRNA -1018, has turned into a profit for the company. Moderna’s win After learning of the cancellation ...
